Essa Bancorp (ESSA) shares rallied 5.4% in the last trading session to close at $19.50. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.5% gain over the past four weeks. Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements ...

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will present at the JonesHealthcare Seaside Summit on Monday, July 15, 2024 at 11:00 a.m. PT. David R. Parkinson, President and Chief Executive Officer, will host the presentation and will also participate in a panel discussion ...

Core Insights - ESSA Pharma Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer treatment [3] Group 1: Upcoming Presentation - ESSA will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 12:30 p.m. ET in New York [1] - The presentation will be hosted by David R. Parkinson, President and CEO, and David S. Wood, CFO, who will also participate in one-on-one meetings [2] - A live webcast of the presentation will be available on ESSA's website and archived for 90 days post-event [2] Group 2: Company Information - ESSA is dedicated to developing proprietary therapies specifically for prostate cancer patients [3] - Additional information about the company can be found on its website and social media platforms [3]

Business Overview EPIX is a clinical-stage pharmaceutical company focused on developing therapies for prostate cancer. It was founded in 2009 and operates in Houston, San Francisco, and Vancouver. Today, EPIX's science focuses on therapies designed to disrupt the androgen receptor [AR] using N-terminal Domain [NTD] inhibitors called Anitens to inhibit cancer growth. Prostate cancer is the most common cancer in men in the U.S. and the second cause of male cancer deaths. About 1 in 8 men will be diagnosed wit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to __________ Commission File No. 001-33384 ESSA Bancorp, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 20-8023072 (State or other jurisdictio ...

Financial Performance - Net income for the second quarter of 2024 was $4.6 million, or $0.48 per diluted share, compared to $4.7 million, or $0.48 per diluted share, for the same period in 2023[3] - Net income for the three months ended March 31, 2024, was $4,562 thousand, slightly down from $4,685 thousand in the same period of 2023, a decrease of about 2.62%[36] - Earnings per share remained stable at $0.48 for both the three months ended March 31, 2024, and 2023[36] Interest Income and Margin - Total interest income increased by 27.9% to $25.7 million in the second quarter of 2024, and rose by 33.8% to $51.7 million in the first half of 2024 compared to the same periods in 2023[9] - Total interest income rose to $25,650 thousand for the three months ended March 31, 2024, up from $20,054 thousand in the same period of 2023, marking an increase of approximately 28.06%[36] - Net interest margin improved to 2.87% for the second quarter of 2024, compared to 2.79% for the first quarter of 2024[11] - The net interest margin decreased to 2.87% for the three months ended March 31, 2024, compared to 3.34% for the same period in 2023[37] Loans and Deposits - Total net loans increased to $1.71 billion at March 31, 2024, up from $1.68 billion at September 30, 2023, with commercial real estate loans growing by 4.2% to $856.1 million[11] - Total deposits were $1.45 billion at March 31, 2024, with lower-cost core deposits comprising 69.3% of total deposits[11] - Deposits decreased significantly from $1,661,016 thousand as of September 30, 2023, to $1,446,305 thousand as of March 31, 2024, a decline of about 12.92%[34] Assets and Liabilities - Total assets decreased from $2,293,246 thousand as of September 30, 2023, to $2,191,102 thousand as of March 31, 2024, representing a decline of approximately 4.45%[34] - Total liabilities decreased from $2,073,538 thousand as of September 30, 2023, to $1,967,562 thousand as of March 31, 2024, a reduction of approximately 5.11%[34] Noninterest Expense and Credit Quality - Noninterest expense for the second quarter of 2024 was $11.7 million, an increase from $11.3 million in the same quarter of 2023[21] - Total noninterest expense increased to $11,714 thousand for the three months ended March 31, 2024, compared to $11,292 thousand in the same period of 2023, an increase of about 3.73%[36] - The allowance for credit losses to total loans was 0.89% at March 31, 2024, down from 1.09% at September 30, 2023[25] - Nonperforming assets were $14.0 million, or 0.64% of total assets, at March 31, 2024, compared to $14.4 million, or 0.63%, at September 30, 2023[25] Capital Ratios - The Tier 1 capital ratio was 9.5% at March 31, 2024, exceeding regulatory standards for a well-capitalized institution[28] - Tangible book value per share increased to $20.70 at March 31, 2024, from $19.80 at September 30, 2023[28] Share Information - Average shares outstanding (basic) decreased from 9,717,899 for the three months ended March 31, 2023, to 9,513,798 for the same period in 2024, a decrease of approximately 2.11%[37]

Essa Bancorp (ESSA) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.48 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.14%. A quarter ago, it was expected that this bank would post earnings of $0.46 per share when it actually produced earnings of $0.45, delivering a surprise of -2.17%.Over the last four quarters, the company has su ...

Essa Bancorp (ESSA) shares rallied 7.1% in the last trading session to close at $17.21. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.8% loss over the past four weeks.With the U.S. economy showing no signs of slowing down and the Federal Reserve still expected to cut rates this year, banking sector is in the spotlight. Hence, investors are showing optimistic stance on the sector and this is likely to hav ...

Essa Bancorp (ESSA) shares ended the last trading session 7.2% higher at $18.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.7% loss over the past four weeks.After getting hammered because of industry-wide concern related to commercial real estate (CRE) loans, shares of Essa Bancorp are showing signs of improvement. Given the company’s notable CRE loan exposure, the Federal Reserve’s signal of rate cuts later ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to __________ Commission File No. 001-33384 ESSA Bancorp, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 20-8023072 (State or other jurisdic ...